Search Share Prices
Indivior launches monthly opioid addiction injection in US
Indivior has launched its new once-a-month version of its opioid addiction treatment in the US amid a Donald Trump's 'war on opioid addiction'.
The FTSE 250 company's Sublocade, which is a extended-release 'depot' dose of buprenorphine, a new formulation of its Suboxone sub-lingual film, can be prescribed and administered by healthcare providers via subcutaneous injection.
Sublocade has been approved by the US Food & Drug Administration for the treatment of moderate to severe opioid use disorder in adult patients who have initiated treatment with a transmucosal buprenorphine-containing product followed by dose adjustment for a minimum of seven days. It should be administered only by healthcare providers and should be used as part of a complete treatment program that includes counseling and psychosocial support, Indivior stressed.
Indivior last month increased its financial provisions over potential US litigation by $210m and, having reached a settlement with one generic rival during the year, said it was continuing "active discussions with the various governmental and other entities about possible resolutions to their investigative and antitrust litigation matters".
"We're committed to helping the patients, families and communities impacted by the opioid epidemic, and delivering new treatment options for moderate to severe opioid use disorder," said Richard Simkin, Indivior's chief commercial and strategy officer.
"The availability of SUBLOCADE, with our comprehensive support services, marks a pivotal milestone for our company."
In January, the company's shares received a boost after rival Camurus's comparable depot product was not approved by the FDA.
But Indivior last month it was still being dogged by plenty of legal matters, with total legal provisions standing at $438m, up from $228m. Management is continuing "active discussions with the various governmental and other entities about possible resolutions to their investigative and antitrust litigation matters" and the final aggregate settlement amount "may be materially different" from its current provisions.